combination chemotherapy in treating older patients with non-hodgkin's lymphoma

Conditions: Lymphoma

Summary: rationale: drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. combining more than one drug may kill more tumor cells. purpose: phase ii trial to study the effectiveness of combination chemotherapy in treating older patients who have non-hodgkin's lymphoma.

objectives: * determine the complete remission (cr) rate and duration of cr in frail elderly patients with diffuse large b-cell or peripheral t-cell non-hodgkin's lymphoma treated with cyclophosphamide, vincristine, and prednisone. * determine the time to progression and overall survival of patients treated with this regimen. * determine the severe toxicity rate of this regimen in these patients. * assess the quality of life of patients treated with this regimen. outline: this is a multicenter study. patients receive cyclophosphamide iv and vincristine iv on day 1 and oral prednisone on days 1-5. treatment repeats every 3 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. patients with stage i or ii non-hodgkin's lymphoma (nhl), no baseline lactate dehydrogenase (ldh) elevation, baseline who performance status 0-1, and longest tumor diameter of less than 5 cm, who achieve partial response (pr) or complete response (cr), receive 1 additional course of chemotherapy. patients then undergo involved-field radiotherapy once daily 5 days a week for 3.5-4 weeks. patients with stage i or ii nhl, a baseline ldh elevation, and/or baseline who performance status 2-4, and/or longest tumor diameter of at least 5 cm, who achieve pr or cr, receive 3 additional courses of chemotherapy. patients then undergo involved-field radiotherapy once daily 5 days a week for 3.5-4 weeks. patients with stage iii or iv nhl who achieve cr or pr receive 3 additional courses of chemotherapy. patients then undergo consolidative radiotherapy once daily 5 days a week for 2.5-3 weeks. quality of life is assessed at baseline, after the third chemotherapy course, at the end of chemotherapy, every 6 months for 3 years, and then annually thereafter. patients are followed every 3 months for 3 years, every 6 months for 2 years, and then annually thereafter. projected accrual: a total of 29-56 patients will be accrued for this study within 12-18 months.

Eligibility criteria:
disease characteristics: * diagnosis of diffuse large b-cell or peripheral t-cell non-hodgkin's lymphoma (nhl) * no burkitt's-like lymphoma * small cells in bone marrow allowed * previously untreated nhl * at least 1 measurable lesion * at least 1.1 cm * poor physiological status with at least 1 of the following: * who performance status of 3-4 * lvef less than 50% * creatinine clearance less than 50 ml/min * neutrophil count no greater than 1,500/mm\^3 * platelet count no greater than 100,000/mm\^3 * concurrent severe disease that would preclude cyclophosphamide, vincristine, prednisolone, and doxorubicin * no cerebral or meningeal involvement patient characteristics: age: * 70 and over performance status: * see disease characteristics life expectancy: * not specified hematopoietic: * see disease characteristics hepatic: * not specified renal: * see disease characteristics other: * hiv negative * no other malignancy within the past 5 years except adequately treated basal cell skin cancer, curatively treated carcinoma in situ of the cervix, or curatively treated solid tumor * no active infection * no psychological, familial, sociological, or geographical condition that would preclude study participation prior concurrent therapy: biologic therapy: * not specified chemotherapy: * see disease characteristics endocrine therapy: * not specified radiotherapy: * not specified surgery: * not specified other: * no other concurrent investigational drugs * no other concurrent antineoplastic agents

Keywords: stage i adult diffuse large cell lymphoma stage iii adult diffuse large cell lymphoma stage iv adult diffuse large cell lymphoma contiguous stage ii adult diffuse large cell lymphoma noncontiguous stage ii adult diffuse large cell lymphoma angioimmunoblastic t-cell lymphoma